Trial reportNature cancer2023
PD-L1 blockade in combination with carboplatin as immune induction in metastatic lobular breast cancer: the GELATO trial.
Trial report in Nature cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03147040 (AssessinG Efficacy of Carboplatin and ATezOlizumab in Metastatic Lobular Breast Cancer), which is not on this map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
AssessinG Efficacy of Carboplatin and ATezOlizumab in Metastatic Lobular Breast Cancer: GELATO-trial
Who cites it
22 citing papers in PubMed, 36 citations in OpenAlex.
- Pembrolizumab and Paclitaxel in Patients with HR+/HER2- Breast Cancer with HER2-Enriched or Basal-like Subtypes.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Trial
- Toward targeted therapeutics for lobular breast cancer.The Journal of clinical investigation · 2026Review
- E-cadherin inactivation shapes tumor microenvironment specificities in invasive lobular breast cancer.Nature communications · 2026Article
- Clinical and histopathological characterization of metastatic lobular breast cancer: lessons learned from post-mortem tissue donation programs.NPJ breast cancer · 2026Article
- Targeting the tripartite axis of immune-metabolic-spatial crosstalk to overcome therapy resistance in breast cancer.Frontiers in immunology · 2026Review
- Progress and prospects of metal-based immunotherapy in breast cancer.Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine · 2025Review
- Pathological complete response and survival after neoadjuvant chemotherapy in patients with stage I TNBC: a registry-based study.ESMO open · 2025Article
- Emerging Biomarkers to Predict Immunotherapy Response in Breast Cancer.Current oncology reports · 2025Review
- Review
- Unraveling complexity and leveraging opportunities in uncommon breast cancer subtypes.NPJ breast cancer · 2025Review
- The immunopeptidome of colon cancer cells treated with topoisomerase inhibiting drug reveals differential as well as common endogenous protein sampling and display of MHC I-associated peptides.Molecular & cellular oncology · 2025Article
- E-Cadherin-Mediated Cell-Cell Adhesion and Invasive Lobular Breast Cancer.Advances in experimental medicine and biology · 2025Review
- Clinical characteristics and prognosis of breast cancer patients with ovarian metastases.Frontiers in oncology · 2025Article
- Immunotherapy for hormone receptor‒positive HER2-negative breast cancer.NPJ breast cancer · 2024Review
- Review
- International survey on invasive lobular breast cancer identifies priority research questions.NPJ breast cancer · 2024Article
- Reporting on invasive lobular breast cancer in clinical trials: a systematic review.NPJ breast cancer · 2024Review
- Review
- Review
- Tumor Mutational Burden in Breast Cancer: Current Evidence, Challenges, and Opportunities.Cancers · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
28 authors at 6 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Invasive lobular breast cancer (ILC) is the second most common histological breast cancer subtype, but ILC-specific trials are lacking. Translational research revealed an immune-related ILC subset, and in mouse ILC models, synergy between immune checkpoint blockade and platinum was observed. In the phase II GELATO trial ( NCT03147040 ), patients with metastatic ILC were treated with weekly carboplatin (area under the curve 1.5 mg ml
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.